Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 164

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 164
---
        1.1 - 5.0 years
        0.9 - 4.7 years

        Common stock market price
        $2.01 - $2.27
         
        $1.45

        Risk-free interest rate
        4.5% - 5.1%
        3.81% - 4.63%

        Expected volatility
        117.0% - 127.2%
        92.2% - 99.79%

       The table below provides a summary of the fair value of the Company’s warrant liability during year ended December 31, 2024 (in thousands). As of December 31, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the year ended December 31, 2023 was immaterial.   

        Twelve Months Ended December 31, 2024

        Warrant liability

        Beginning balance
         
        $
        —

        Issuance of warrants

        10,854

        Change in fair value of warrants

        (5,654
        )

        Reclassification to equity

        (5,200
        )

        Ending balance
         
        $
        —

       Nonfinancial Assets and LiabilitiesThe Company applies fair value techniques on a non-recurring basis, if and when necessary, associated with: (1) valuing potential impairment losses related to goodwill and intangible assets which are accounted for pursuant to the authoritative guidance for intangibles—goodwill and other; and (2) valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment. There was no impairment related to long lived assets, intangible assets, or goodwill during the years ended December 31, 2024 or 2023. 

4.      Investments As of December 31, 2024, the Company had total investments of $3.5 million of money market accounts, treasury bills, and government agency bonds, with total amortized cost and fair value of $3.5 million. These investments are collateralized marketable securities as described in footnote 10. The Company did not have investments as of December 31, 2023. As of December 31, 2024, the Company classified available-for-sales as short-term investments in the consolidated balance sheet because the maturity dates were less than one